What to Know About Ozempic and Gastroparesis in Michigan
Latest update (2026-01)
FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]
From General Health Science to Targeted Legal Guidance
If you or a loved one has experienced persistent nausea, vomiting, or abdominal pain while taking Ozempic, you may be wondering about the connection to gastroparesis. Decades of pharmacovigilance have established that certain medications can slow gastric emptying, and recent reports highlight this potential side effect with GLP-1 receptor agonists. This page covers what current research says about Ozempic and gastroparesis, who may be at higher risk, and why monitoring matters in Michigan.
Ozempic and Gastroparesis: The Medical Evidence
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacological action involves slowing gastric emptying, which contributes to glycemic control but also underlies a spectrum of gastrointestinal adverse effects. Among these, gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction—has emerged as a significant clinical concern. This narrative examines the evidence linking Ozempic to gastroparesis, the adequacy of warnings, and settlement-related considerations for affected patients in Michigan, with a focus on the statute of limitations. Clinical presentation of gastroparesis includes nausea, vomiting, early satiety, postprandial fullness, abdominal pain, and bloating. Diagnosis typically involves gastric emptying scintigraphy showing delayed emptying. In Ozempic clinical trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: placebo 15.3%, Ozempic 0.5 mg 32.7%, and Ozempic 1 mg 36.4% (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal symptoms, which can mimic or exacerbate gastroparesis.
Mechanism and Warning Adequacy
The mechanistic pathway linking Ozempic to gastroparesis involves GLP-1 receptor agonist-induced delay in gastric emptying. This effect is pharmacologically intended but can become pathological in susceptible individuals, leading to symptomatic gastroparesis. The label does not explicitly list gastroparesis as a warning or adverse reaction, but it does include warnings for hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific gastroparesis warning raises questions about the adequacy of warnings. Patients may not be adequately informed about the risk of developing gastroparesis, particularly when symptoms like nausea and vomiting are common and often attributed to dose escalation rather than a distinct condition. For affected patients in Michigan, settlement-related considerations depend on the statute of limitations for product liability claims. Michigan law generally requires claims to be filed within three years of the injury or when the injury should have been discovered. The timeline between exposure to Ozempic and documented harm is critical. Gastrointestinal symptoms often emerge during dose escalation, but gastroparesis may develop insidiously over weeks to months. Patients who experienced persistent nausea, vomiting, or abdominal pain while on Ozempic should document the onset and duration of symptoms, as well as any diagnostic evaluations for gastroparesis. The statute of limitations may begin when a patient is diagnosed with gastroparesis or when they reasonably should have connected their symptoms to Ozempic use.
Settlement Considerations and Legal Context
Settlement considerations also involve the strength of evidence linking Ozempic to gastroparesis. While clinical trial data show increased gastrointestinal adverse reactions, direct evidence of gastroparesis as a distinct adverse event is limited. However, the pharmacological mechanism and case reports support a causal association. Patients with documented gastroparesis after Ozempic use may have viable claims if they can demonstrate that the manufacturer failed to provide adequate warnings. The adequacy of warnings is a key risk anchor: the label does not mention gastroparesis, and the gastrointestinal adverse reactions listed are common and often transient. This may be insufficient to alert patients and healthcare providers to the risk of persistent gastroparesis. In summary, Ozempic is associated with a dose-dependent increase in gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, which can be consistent with gastroparesis. The label lacks a specific warning for gastroparesis, potentially leaving patients uninformed. Michigan patients who developed gastroparesis after Ozempic use should be aware of the three-year statute of limitations from the date of diagnosis or discovery of the injury. Documenting the timeline of exposure, symptom onset, and diagnosis is essential for any potential settlement or legal claim.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Ozempic gastroparesis claims in Michigan?
Michigan law generally requires product liability claims to be filed within three years of the injury or when the injury should have been discovered. For Ozempic-related gastroparesis, the clock may start ticking from the date of diagnosis or when a patient reasonably should have connected their symptoms to Ozempic use. It is crucial to consult an attorney promptly to avoid missing this deadline.
Does Ozempic's label warn about gastroparesis?
No, the Ozempic label does not explicitly list gastroparesis as a warning or adverse reaction. It includes warnings for hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but the absence of a specific gastroparesis warning may be considered inadequate by some plaintiffs.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.